M- Health Market is expected to grow at a tremendous rate of 36.5% of CAGR by 2022

Market Highlights

Market research future published a half-cooked research report on Asia-Pacific Glaucoma Treatment Market. The Asia Pacific Glaucoma Treatment market is expected to grow at a CAGR of ~ 7.5 % during the period 2017 to 2023.

Glaucoma is the buildup of pressure due to accumulation of eye fluids which may result in permanent blindness due to damage to the eye nerve endings. In fact glaucoma is the second most reason after cataracts causing permanent blindness. Open angle glaucoma (OAG) is the most common type of glaucoma followed by closed angle glaucoma (CAG) and these two account for greater than 50% of glaucoma cases. Other types of glaucoma are pigmentary glaucoma, pseudoexfoliation glaucoma and normal-tension glaucoma.

The market for glaucoma treatment is growing due to factors such as rising geriatric population and rising cases of diseases such as diabetes. Other market drivers include increasing awareness, growing healthcare expenditure and screening rates.

Test the market data and market information presented through more than 60 market data tables and figures spread over 70 numbers of pages of the project report. Avail the in-depth table of content (TOC) & market synopsis on “Asia-Pacific Glaucoma Treatment Market Research Report - Forecast to 2023”.

The constraints of the market are excellent efficacy of the present drugs especially the prostaglandin analogs which are the market leaders. The other constraints are the low penetration of healthcare in poor regions of Asia, the neglect of eye care as compared to other healthcare sectors and the high cost of eye surgeries.

The market developments include the technological advancements in surgeries such as advanced technology glaucoma surgery (ATGS) which involves implant of a drainage device so as to drain the fluids. Micro-invasive glaucoma surgery (MIGS) drainage implants dominate the advanced technology glaucoma surgery (ATGS) devices and are expected to account for most of the growth.
Another development includes goggles that help normalize the difference between intraocular pressure (IOP) and cerebrospinal fluid.

Access Report Details @ https://www.marketresearchfuture.com/reports/asia-pacific-glaucoma-treatment-market-2962

Asia-Pacific Glaucoma Treatment Market:
The Asia-Pacific Glaucoma Treatment Market has been evaluated as a growing market and it is expected that the market will touch high growth figures in future. The Asia Pacific Glaucoma Treatment market is expected to grow with CAGR of 7.5 % during the forecast period.

Major Key Players
• Novartis AG,
• Pfizer Inc.,
• Allergan,
• Merck & Co.,
• Ocular Therapeutix Inc,
• pSivida Corp,
• Icon Bioscience Inc,
• Amorphex Therapeutics LLC.,
• Ellex, Quantel,
• Lumenis,
• Lightmed

Regional Analysis:
The healthcare sector of Asia Pacific varies immensely by countries. However the Asia Pacific region has lower public sector expenditure and most treatments involve out of pocket expenditure. Further the eye care has been a neglected segment especially in the poor countries of Asia Pacific region. Japan and South Korea are the leading markets while China will be the fastest growing due to rising healthcare expenditure and faster economic growth. Also the presence of strong generics especially in nations like India will lead to volume growth of anti-glaucoma drugs. The surgery market however will see fastest growth in Japan as compared to developing parts of Asia Pacific.

Asia-Pacific Glaucoma Treatment Market has been segmented on the basis of disease indication which comprises Closed Angle Glaucoma (CAG), open angle glaucoma (OAG), secondary glaucoma, congenital glaucoma and other. On the basis of drug class; market is segmented into prostaglandin analogs (PGAS), alpha agonist, beta blockers, cholinergic drugs, carbonic anhydrase inhibitors, and others. On the basis of surgery; market is segmented into laser iridotomy, laser trabeculoplasty, aqueous shunt surgery and peripheral iridectomy. On the basis of end users; market is segmented into hospitals and home users

Request a Copy of Sample Report @ https://www.marketresearchfuture.com/enquiry/2962

Brief TOC
1 Introduction
1.1 Definition
1.2 Scope of Study
1.3 Research Objective
1.4 Assumptions & Limitations
1.5 Market Structure:
2 Research Methodology
2.1 Research Process
2.2 Primary Research
2.3 Secondary Research
3 Market Dynamics
3.1 Drivers
3.2 Restraints
3.3 Opportunities
3.4 Challenges
3.5 Macroeconomic Indicators
4 Market Factor Analysis
Continued…..

Browse Related Report

Global anti-asthma drugs market Information, by type of asthma (allergic (extrinsic) and non-allergic (intrinsic) asthma), by asthma trigger type (child-onset asthma, adult-onset asthma, exercise-induced asthma, cough-induced asthma, occupational asthma, nocturnal asthma, steroid-resistant asthma (severe asthma)), by drug class (bronchodilators (beta agonists, anti-cholinergics, xanthines), leukotriene antagonists, mast cell stabilizers, corticosteroids, monoclonal antibody), by therapy (reliever treatment and maintenance treatment) and by route of administration (oral, inhaled, intravenous, subcutaneous)- Forecast to 2022

https://www.marketresearchfuture.com/reports/anti-asthma-drugs-market

About Market Research Future:
At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
MRFR team have supreme objective to provide the optimum quality market research and intelligence services to our clients. Our market research studies by products, services, technologies, applications, end users, and market players for global, regional, and country level market segments, enable our clients to see more, know more, and do more, which help to answer all their most important questions.

Contact:
Akash Anand,
Market Research Future
+1 646 845 9312
Email: akash.anand@marketresearchfuture.com

This release was published on openPR.